<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News and Trends on Pharma Industry Production &amp; Manufacturing</title>
	<atom:link href="https://www.worldpharmatoday.com/production-manufacturing/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Tue, 25 Aug 2026 10:47:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>News and Trends on Pharma Industry Production &amp; Manufacturing</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Trace-Level Testing, Validation Pressure, and the New Demands on Pharma Labs</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/trace-level-testing-validation-pressure-and-the-new-demands-on-pharma-labs/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 25 Aug 2026 10:47:20 +0000</pubDate>
				<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/trace-level-testing-validation-pressure-and-the-new-demands-on-pharma-labs/</guid>

					<description><![CDATA[<p>As pharmaceutical analytical workflows grow more demanding, labs are under increasing pressure to balance trace-level accuracy, validation requirements, documentation, and faster development timelines. By Brian Alexander, Ph.D., geochemist and Chief Technical Officer at Inorganic Ventures, a manufacturer of inorganic certified reference materials. As pharmaceutical manufacturers push toward lower detection limits, tighter impurity thresholds, and faster [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/trace-level-testing-validation-pressure-and-the-new-demands-on-pharma-labs/">Trace-Level Testing, Validation Pressure, and the New Demands on Pharma Labs</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Eli Lilly&#8217;s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania</title>
		<link>https://www.worldpharmatoday.com/news/eli-lillys-3-5-billion-manufacturing-campus-advances-in-upper-macungie-pennsylvania/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 21 Aug 2026 13:33:12 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/eli-lillys-3-5-billion-manufacturing-campus-advances-in-upper-macungie-pennsylvania/</guid>

					<description><![CDATA[<p>A planned $3.5 billion pharmaceutical manufacturing campus in Upper Macungie Township, Pennsylvania, has advanced through the local development process after the Upper Macungie Planning Commission recommended final subdivision and land development approval on August 19, 2026. Known as Project Kennedy, the development by Eli Lilly calls for a 797,432-square-foot manufacturing campus on approximately 150 acres [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/eli-lillys-3-5-billion-manufacturing-campus-advances-in-upper-macungie-pennsylvania/">Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Genentech Completes Structural Framework at New NC Manufacturing Facility</title>
		<link>https://www.worldpharmatoday.com/news/genentech-completes-structural-framework-at-new-nc-manufacturing-facility/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 20 Aug 2026 12:46:41 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/genentech-completes-structural-framework-at-new-nc-manufacturing-facility/</guid>

					<description><![CDATA[<p>Genentech raised the final beam of its new Holly Springs, North Carolina manufacturing facility on August 18, marking the completion of the structural framework for what will become the company&#8217;s first East Coast manufacturing site in the United States. The topping out ceremony represents an on-time construction milestone for Genentech, a member of the Roche [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/genentech-completes-structural-framework-at-new-nc-manufacturing-facility/">Genentech Completes Structural Framework at New NC Manufacturing Facility</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351</title>
		<link>https://www.worldpharmatoday.com/news/chugai-pharmaceutical-and-gsk-sign-exclusive-license-agreement-for-anti-dengue-antibody-aid351/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 20 Aug 2026 07:22:24 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Vaccination]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/chugai-pharmaceutical-and-gsk-sign-exclusive-license-agreement-for-anti-dengue-antibody-aid351/</guid>

					<description><![CDATA[<p>Japan-based Chugai Pharmaceutical has entered into an exclusive license agreement with British pharmaceutical company GlaxoSmithKline (GSK) for the anti-dengue virus antibody known as AID351, in a move that advances global efforts to combat one of the world&#8217;s most widespread tropical diseases. Under the terms of the agreement, GSK obtains an exclusive, worldwide license from Chugai [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/chugai-pharmaceutical-and-gsk-sign-exclusive-license-agreement-for-anti-dengue-antibody-aid351/">Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Bilayer Tablets Supporting Combination Drug Delivery</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/bilayer-tablets-supporting-combination-drug-delivery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 14 Aug 2026 14:16:06 +0000</pubDate>
				<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/bilayer-tablets-supporting-combination-drug-delivery/</guid>

					<description><![CDATA[<p>The pharmaceutical industry has increasingly turned toward fixed-dose combinations to improve patient compliance and therapeutic efficacy. One of the most technologically advanced methods for achieving this is through the production of multilayer solid dosage forms. The utilization of bilayer tablets supporting combination drug delivery provides a unique solution for incorporating two or more active pharmaceutical [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/bilayer-tablets-supporting-combination-drug-delivery/">Bilayer Tablets Supporting Combination Drug Delivery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Multiparticulate Capsules Enhancing Oral Dose Delivery</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/multiparticulate-capsules-enhancing-oral-dose-delivery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 14 Aug 2026 13:48:59 +0000</pubDate>
				<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/multiparticulate-capsules-enhancing-oral-dose-delivery/</guid>

					<description><![CDATA[<p>The development of oral solid dosage forms has evolved from simple monolithic tablets to complex systems designed to provide precise control over drug release. Among the most effective of these systems are multiparticulate dosage forms, which consist of numerous small discrete units such as pellets, beads, or granules enclosed within a capsule shell. The utilization [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/multiparticulate-capsules-enhancing-oral-dose-delivery/">Multiparticulate Capsules Enhancing Oral Dose Delivery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>HPMC Capsules Supporting Flexible Oral Drug Formulation</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/hpmc-capsules-supporting-flexible-oral-drug-formulation/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 14 Aug 2026 13:43:15 +0000</pubDate>
				<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/hpmc-capsules-supporting-flexible-oral-drug-formulation/</guid>

					<description><![CDATA[<p>The pharmaceutical industry has seen a clear shift toward the use of non-animal derived materials in oral solid dosage forms. Among these innovations, the adoption of hydroxypropyl methylcellulose capsules has emerged as a preferred solution for complex drug delivery challenges. The technical advantages of HPMC capsules supporting flexible oral drug formulation are rooted in their [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/hpmc-capsules-supporting-flexible-oral-drug-formulation/">HPMC Capsules Supporting Flexible Oral Drug Formulation</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Wet Granulation Strategies Improving Oral Solid Dose Uniformity</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/wet-granulation-strategies-improving-oral-solid-dose-uniformity/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 14 Aug 2026 13:32:37 +0000</pubDate>
				<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/wet-granulation-strategies-improving-oral-solid-dose-uniformity/</guid>

					<description><![CDATA[<p>In the production of oral solid dosage forms, achieving a high degree of content uniformity is essential for ensuring that every tablet contains the correct amount of the active pharmaceutical ingredient. One of the most critical unit operations for achieving this goal is granulation, a process that enlarges particle size to improve flowability and compressibility. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/wet-granulation-strategies-improving-oral-solid-dose-uniformity/">Wet Granulation Strategies Improving Oral Solid Dose Uniformity</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Visual Inspection Technologies Strengthening OSD Quality Control</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/visual-inspection-technologies-strengthening-osd-quality-control/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 14 Aug 2026 13:06:10 +0000</pubDate>
				<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/visual-inspection-technologies-strengthening-osd-quality-control/</guid>

					<description><![CDATA[<p>The pharmaceutical manufacturing sector continues to face significant pressure to improve product reliability while maintaining high throughput speeds. Within oral solid dosage production, the necessity of absolute precision in identifying physical defects has led to the adoption of sophisticated monitoring systems. The implementation of visual inspection technologies strengthening OSD quality control represents a critical evolution [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/visual-inspection-technologies-strengthening-osd-quality-control/">Visual Inspection Technologies Strengthening OSD Quality Control</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Container-Equipment Interface Data Improving Capping Validation</title>
		<link>https://www.worldpharmatoday.com/packaging-labelling/container-equipment-interface-data-improving-capping-validation/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 10 Aug 2026 09:36:23 +0000</pubDate>
				<category><![CDATA[Packaging & Labelling]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/container-equipment-interface-data-improving-capping-validation/</guid>

					<description><![CDATA[<p>The validation of sterile fill finish operations is one of the most rigorous requirements in pharmaceutical manufacturing, necessitating a comprehensive demonstration that the equipment consistently produces a product meeting its predetermined specifications. Within this framework, the capping process is uniquely challenging because it involves the complex mechanical interaction of three distinct primary packaging components with [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/packaging-labelling/container-equipment-interface-data-improving-capping-validation/">Container-Equipment Interface Data Improving Capping Validation</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
